0000896262-22-000028.txt : 20220502 0000896262-22-000028.hdr.sgml : 20220502 20220502165100 ACCESSION NUMBER: 0000896262-22-000028 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220421 FILED AS OF DATE: 20220502 DATE AS OF CHANGE: 20220502 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Muscato Nick CENTRAL INDEX KEY: 0001923993 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24260 FILM NUMBER: 22882811 MAIL ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMEDISYS INC CENTRAL INDEX KEY: 0000896262 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 113131700 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 BUSINESS PHONE: 2252922031 MAIL ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 FORMER COMPANY: FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP DATE OF NAME CHANGE: 19940819 FORMER COMPANY: FORMER CONFORMED NAME: M&N CAPITAL CORP DATE OF NAME CHANGE: 19930125 3 1 wf-form3_165152464411718.xml FORM 3 X0206 3 2022-04-21 0 0000896262 AMEDISYS INC AMED 0001923993 Muscato Nick 3854 AMERICAN WAY SUITE A BATON ROUGE LA 70816 0 1 0 0 Chief Strategy Officer Common Stock 3402 D Common Stock 213 I By 401(k) Plan Stock Option (Right to Buy) 95.76 2028-07-25 Common Stock 272.0 D Stock Option (Right to Buy) 132.41 2029-07-25 Common Stock 320.0 D Stock Option (Right to Buy) 214.74 2030-07-25 Common Stock 563.0 D Stock Option (Right to Buy) 264.0 2031-07-25 Common Stock 708.0 D Stock Option (Right to Buy) 143.25 2032-07-25 Common Stock 2040.0 D Restricted Stock Unit (Performance-Based Vesting) Common Stock 1746.0 D Represents restricted stock units ("RSUs") that vest based on the passage of time. 1,824 of the RSUs vest on July 25, 2022, 386 of the RSUs vest on July 25, 2023, 247 of the RSUs vest on July 25, 2024, 72 of the RSUs vest on July 25, 2025, 218 of the RSUs vest on February 20, 2023, 218 of the RSUs vest on February 20, 2024, 218 of the RSUs vest on February 20, 2025 and 219 of the RSUs vest on February 20, 2026, assuming the Reporting Person remains continuously employed by the Issuer on each such vesting date, subject to certain pro-rated vesting provisions as provided in the award agreement for the RSUs. The information in this report is based on a plan statement dated as of March 31, 2022. The Stock Options are subject to time-based vesting conditions and will vest on July 25, 2022, provided that the Reporting Person remains continuously employed by the Issuer on such date, subject to pro-rated vesting provisions as provided in the award agreement for the Stock Options. The Stock Options are subject to time-based vesting conditions. 107 Stock Options vested on July 25, 2021, 107 Stock Options will vest on July 25, 2022 and 106 Stock Options will vest on July 25, 2023, provided that the Reporting Person remains continuously employed by the Issuer on each such date, subject to pro-rated vesting provisions as provided in the award agreement for the Stock Options. The Stock Options are subject to time-based vesting conditions. 140 Stock Options vested on July 25, 2021, and 141 Stock Options will vest on each of July 25, 2022, July 25, 2023 and July 25, 2024, provided that the Reporting Person remains continuously employed by the Issuer on each such date, subject to pro-rated vesting provisions as provided in the award agreement for the Stock Options. The Stock Options are subject to time-based vesting conditions. 177 Stock Options vest on each of July 25, 2022, July 25, 2023, July 25, 2024 and July 25, 2025, provided that the Reporting Person remains continuously employed by the Issuer on each such date, subject to pro-rated vesting provisions as provided in the award agreement for the Stock Options. The Stock Options are subject to time-based vesting conditions. 510 Stock Options vest on each of July 25, 2023, July 25, 2024, July 25, 2025 and July 25, 2026, provided that the Reporting Person remains continuously employed by the Issuer on each such date, subject to pro-rated vesting provisions as provided in the award agreement for the Stock Options. The performance-based RSUs will vest based on certification of achievement of an identified performance measure for 2022, with additional time-based vesting in equal 25% installments on each of the certification date and February 20, 2024, 2025 and 2026, assuming the Reporting Person remains continuously employed on the vesting date. The amount reported represents the amount of shares payable at target performance; the Reporting Person could earn 0%-200% of the amount reported depending on the level of performance achieved. Exhibit 24.1 - Power of Attorney Jennifer Guckert Griffin, pursuant to a power of attorney 2022-05-02 EX-24 2 a06363073.htm MUSCATO POWER OF ATTORNEY Document

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Jennifer Guckert Griffin and David L. Kemmerly, signing singly, the undersigned’s true and lawful attorney-in-fact to:
1.    execute for and on behalf of the undersigned, in the undersigned’s individual capacity, a Form ID and Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the “Exchange Act”);

2.    do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute a Form ID and any Forms 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and

3.    take any and all other actions of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned’s responsibilities to comply with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by Amedisys, Inc., unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed on April 7, 2022.

/s/ Nick Muscato                
Nick Muscato
{06363073.1}